Evidence map›Paper›PMID 37520136›Full record

ArticleStructural heart : the journal of the Heart Team2023

Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): A Mechanistic Randomized Trial of Ticagrelor Versus Clopidogrel.

David A Zidar, Sadeer Al-Kindi, Chris T Longenecker, Sahil A Parikh, Carl B Gillombardo, Nicholas T Funderburg, Steven Juchnowski, Lauren Huntington, Trevor Jenkins, Christopher Nmai and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Structural heart : the journal of the Heart Team, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

David A ZidarDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Sadeer Al-KindiDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Chris T LongeneckerDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Sahil A ParikhDivision of Cardiology, Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York, USA.
Carl B GillombardoDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Nicholas T FunderburgDivision of Medical Laboratory Science, School of Health and Rehabilitations Sciences, Ohio State University, Columbus, Ohio, USA.
Steven JuchnowskiDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Lauren HuntingtonDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Trevor JenkinsDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Christopher NmaiNew York University Grossman School of Medicine, New York, New York, USA.
Michael OsnardDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Mehdi ShishebhorDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Steven FilbyDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Curtis TatsuokaDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Michael M LedermanDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Eugene BlackstoneDepartment of Population Health and Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Guilherme AttizzaniDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Daniel I SimonDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
University Hospitals of Cleveland · USCase Western Reserve University · USCleveland Clinic · USColumbia University Irving Medical Center · USNew York University · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammation and thrombosis are often linked mechanistically and are associated with adverse events after transcatheter aortic valve replacement (TAVR). High residual platelet reactivity (HRPR) is especially common when clopidogrel is used in this setting, but its relevance to immune activation is unknown. We sought to determine whether residual activity at the purinergic receptor P2Y12 (P2Y12) promotes prothrombotic immune activation in the setting of TAVR. Methods: This was a randomized trial of 60 patients (enrolled July 2015 through December 2018) assigned to clopidogrel (300mg load, 75mg daily) or ticagrelor (180mg load, 90 mg twice daily) before and for 30 days following TAVR. Co-primary endpoints were P2Y12-dependent platelet activity (Platelet Reactivity Units; VerifyNow) and the proportion of inflammatory (cluster of differentiation [CD] 14+/CD16+) monocytes 1 day after TAVR. Results: Compared to clopidogrel, those randomized to ticagrelor had greater platelet inhibition (median Platelet Reactivity Unit [interquartile range]: (234 [170.0-282.3] vs. 128.5 [86.5-156.5], Conclusions: Residual P2Y12 activity after TAVR is common in those treated with clopidogrel but ticagrelor does not significantly alter biomarkers of prothrombotic immune activation. HRPR appears to be an indicator (not a cause) of innate immune activation in this setting.

Indexed as

ClopidogrelInflammationTAVRTicagrelorTranscatheter aortic valve replacement

Identifiers

PMID37520136
PMCPMC10382989
OpenAlexW4367316385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.